{"prompt": "['Product: MK-3475', '132', 'Protocol/Amendment No.: 604-09', '[89]', 'Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-', 'based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3', 'Suppl):324S-339S.', '[90]', 'von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et', 'al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the', 'treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999 Feb; ;17(2):658-', '67.', '[91]', \"O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al.\", 'Phase III trial comparing supportive care alone with supportive care with oral', 'topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006 Dec', '1;24(34):5441-7.', '[92]', 'Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III', 'study of oral compared with intravenous topotecan as second-line therapy in', 'small-cell lung cancer. J Clin Oncol. 2007 May 20;25(15):2086-92 Erratum in:', 'J', 'Clin Oncol. 2007 Aug 1;25(22):3387.', '[93]', 'Graus F, Dalmou J, Rene R, Tora M, Malats N, Verschuuren JJ, et al. Anti-Hu', 'antibodies in patients with small-cell lung cancer: association with complete', 'response to therapy and improved survival. J Clin Oncol. 1997 Aug;15(8):2866-', '72.', '[94', 'Tanio Y, Watanabe M, Osaki T, Tachibana I, Kawase I, Kuritani T, et al. High', 'sensitivity to peripheral blood lymphocytes and low HLA-class I antigen', 'expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity.', 'Jpn J Cancer Res. 1992 Jul;83(7):736-45.', '[95]', 'Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, et al. Lack', 'of class II transactivator causes severe deficiency of HLA-DR expression in small', 'cell lung cancer. J Pathol. 1999 Jan; 187(2): 191-9.', '[96]', 'Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R, et al. Reciprocal', 'CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+', 'regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res.', '2008 Nov 1;14(21):6770-9.', '[97]', 'Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, et al.', 'PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015', 'Feb;51(3):421-6.', '[98]', 'Komiya T, Madan R. PD-L1 expression in small cell lung cancer. Eur J Cancer.', '2015 Sep;51(13):1853-5.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '133', 'Protocol/Amendment No.: 604-09', '[99]', 'Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, et al.', 'Significance of programmed cell death-ligand 1 expression and its association', 'with survival in patients with small cell lung cancer. J Thorac Oncol. 2015', 'Mar;10(3):426-30.', '[100]', 'Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong L, et al. PD-L1 and c-MET', 'expression and survival in patients with small cell lung cancer. Oncotarget.', 'Forthcoming 2016.', '[101]', 'Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, et al.', 'Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small', 'cell lung cancer (SCLC). J Neurooncol. 2016 Oct;130(1): 19-29.', '[102] Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al.', 'Cancer immunology. Mutational landscape determines sensitivity to PD-1', 'blockade in non-small cell lung cancer. Science. 2015 Apr 3;348(6230):124-8.', '[103]', 'Ott PA, Felip E, Hiret S, Kim DW, Morosky A, Saraf S, et al. Pembrolizumab in', 'Patients With Extensive-Stage Small Cell Lung Cancer: Updated Survival Results', 'From KEYNOTE-028. Poster session presented at: IASLC 17th World', 'Conference on Lung Cancer; 2016 Dec 4-7; Vienna, AUT.', '[104] Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et', 'al. Topotecan, a new active drug in the second-line treatment of small-cell lung', 'cancer: a phase II study in patients with refractory and sensitive disease. The', 'European Organization for Research and Treatment of Cancer Early Clinical', 'Studies Group and New Drug Development Office, and the Lung Cancer', 'Cooperative Group. J Clin Oncol. 1997 May;15(5):2090-6.', '[105]', 'Depierre A, von Pawel J, Hans K, Moro D, Clark P, Gatzemeier U, et al.', 'Evaluation of topotecan (Hycamtin) in relapsed small cell lung cancer (SCLC). A', 'multicenter phase II study [abstract]. Lung Cancer. 1997; 18(1 Suppl): 35. Abstract', 'no. 126.', '[106]', 'Eckardt J, Gralla R, Palmer MC, Gandara D, Laplante J, Sandier A, et al.', 'Topotecan (T) as Second-Line Therapy In Patients (Pts) with Small Cell Lung', 'Cancer (SCLC): A Phase II Study [abstract]. Ann Oncol. 1996;7 Suppl 5:107.', 'Abstract no. 513P.', '[107]', 'Eckardt J, Depierre A, Ardizzoni A, Von Pawel J, Fields S. Pooled analysis of', 'topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell', 'lung cancer (SCLC). Proc Am Soc Clin Oncol. 1997;16. Abstract no. 1624.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}